Prostate Cancer Research Institute

PCRI is a 501(c) (3)
Not-for-profit public charity











Prostate Cancer Research Institute
  Donate    Helpline       Decision Aide     About Us      Español Sección en Español
   Events   Newsletter  PCRI Papers      Resources  Search

 

Talks by Dr. Scholz and Dr. Lam - DVDs

Dr. Mark Scholz and Dr. Richard Lam have graciously made available DVDs created from talks they have made to support groups. Prostate Oncology Specialists is a medical group exclusively devoted to caring for men with prostate cancer.

You may request free copies below. Please share them with your support group or with friends who are dealing with prostate cancer. We offer the DVDs for free, because we don’t want men who might benefit from the information to avoid requesting it simply because of cost. If you would like to help defer our cost, so that we can continue to offer such resources, please consider a generous donation to the PCRI today. To donate to PCRI, see our Donations page.

A New Perspective: Look Before You Leap -Mark Scholz, MD

Prostate cancer treatment is rapidly changing. More and more, the disease is being separated into two widely disparate categories: a chronic form that is not life-threatening and an aggressive type that requires combination treatment.

This lecture, by Mark Scholz, MD, focuses on the chronic form of the disease, describing how men can safely forgo immediate radical treatment. This is achieved by a process of close monitoring called Active Surveillance. A third type of prostate cancer falls between the two extremes of chronic and aggressive—it is called intermediate risk. Management of Intermediate Risk prostate cancer with Testosterone Inactivating Pharmaceuticals (TIP) instead of radical therapy is also covered in this lecture.

Systemic Treatments for Prostate Cancer -Richard Lam, MD
Why are medicines for a “localized” cancer needed?

Prostate cancer, contrary to popular belief, is often associated with systemic metastasis—microscopic cancer outside of the gland. Clear bone scans and CT scans can be misleading since they are unable to “see” microscopic disease. Microscopic metastasis may be present if the PSA is rising quickly, multiple biopsy cores are involved with cancer, the Gleason score is greater than 7, the PSA is above 10, or a large nodule is present in the prostate. Men with these adverse risk features receive little, if any benefit when primary therapy consists of prostate surgery or radiation alone.

This lecture, by Richard Lam, MD, focuses on identifying men likely to have micro-metastasis and discusses possible treatments. Systemic therapies include testosterone inactivating pharmaceuticals (TIP), radiation therapy, Taxotere® (docetaxel), immune-based compounds, targeted drugs, and experimental agents.

Testosterone Independent Prostate Cancer -Mark Scholz, MD

Testosterone blockade can control prostate cancer for years. However, when the disease becomes resistant, additional therapy is required. Timing can be crucial—it is important to avoid delaying therapy. Early initiation of treatment increases its effectiveness.

This lecture, by Mark Scholz, MD, explains how to spot the first signs of testosterone resistance so that treatment can start immediately. The principles and proper methods for selecting appropriate therapies are reviewed. Methods for reducing the side-effects of treatment and for handling common emergencies are addressed.

You can order these DVDs online by using this form.



Home    Site Map    About Us     Disclaimer     Contact


Prostate Cancer Research Institute (PCRI)

 

Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.